Back

Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations

European Heart Journal

30 October 2021
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY Pharmacology and Pharmacotherapy

Contributors

Javed Butler
Javed Butler

Author

Stefan D Anker
Stefan D Anker

Author

Gerasimos Filippatos
Gerasimos Filippatos

Author

National & Kapodistrian University of Athens Medical School Athens , Greece

Muhammad Shariq Usman
Muhammad Shariq Usman

Author

Joao Pedro Ferreira
Joao Pedro Ferreira

Author

Faiez Zannad
Faiez Zannad

Author

University of Lorraine Vandoeuvre-Les-Nancy , France

Milton Packer
Milton Packer

Author

You may be interested in
thumbnail
Congress Presentation
Sodium-glucose co-transporter-2 inhibitors improve cardiovascular outcomes in heart failure with reduced ejection fraction regardless of ischemic etiology
27 August 2021
thumbnail
Congress Session
The power of now: a focus on SGLT2 inhibitors for heart failure in the hospital
17 May 2025
thumbnail
Congress Session
Future outlooks into heart failure management in the cardio-renal-metabolic syndrome
19 May 2025
thumbnail
Congress Presentation
Factors associated with oral SGLT2 inhibitor use and prognosis in elderly heart failure patients
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources